Receipt of BNT162b2 KP.2 Vaccine and COVID-19 CVS MinuteClinic Visits in US Adults

Publication date: Jan 16, 2025

Using a test-negative design, we modeled the association between receipt of BNT162b2 KP.2 vaccine and symptomatic COVID-19 among adults testing for SARS-CoV-2 at walk-in clinics in a large US retail pharmacy chain (9/5/2024-12/8/2024). At a median of 37 days post-vaccination, those who received BNT162b2 KP.2 were 48% less likely to test positive.

PDF

Concepts Keywords
Employees Adults
Flu Bnt162b2
Mph1 Cov
Polymerase Covid
Cvs
Days
Kp
Medrxiv
Pfizer
Preprint
Received
Sars
Test
Vaccine
Years

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Coenzyme M
disease IDO history
disease IDO symptom
drug DRUGBANK Methionine
disease MESH chronic condition
disease IDO susceptibility
disease MESH Infectious Diseases

Download Document

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *